An orally bioavailable SARS-CoV-2 main protease inhibitor exhibits improved affinity and reduced sensitivity to mutations
ML2006a4 has improved affinity for SARS-CoV-2 Mpro and reduced sensitivity to mutations conferring resistance to nirmatrelvir or ensitrelvir.